Maria LuÃ-sa Corvo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5426257/publications.pdf

Version: 2024-02-01

58 papers

1,354 citations 21 h-index 36 g-index

59 all docs 59 docs citations

59 times ranked 1885 citing authors

#	Article	IF	Citations
1	Antagonist G-targeted liposomes for improved delivery of anticancer drugs in small cell lung carcinoma. International Journal of Pharmaceutics, 2022, 612, 121380.	5.2	8
2	An In Silico and an In Vitro Inhibition Analysis of Glycogen Phosphorylase by Flavonoids, Styrylchromones, and Pyrazoles. Nutrients, 2022, 14, 306.	4.1	6
3	Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment. Pharmaceutics, 2022, 14, 104.	4.5	15
4	Formulation of spray dried enzymes for dry powder inhalers: An integrated methodology. International Journal of Pharmaceutics, 2022, 615, 121492.	5.2	8
5	Liposomes as Tools to Improve Therapeutic Enzyme Performance. Pharmaceutics, 2022, 14, 531.	4.5	9
6	Inflammatory Pathways and In Vivo Studies of Inflammatory Bowel Disease. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 1-23.	0.1	0
7	Sphingolipid-Enriched Domains in Yeast: Biophysical Properties and Antifungal Interaction. Biophysical Journal, 2021, 120, 45a.	0.5	O
8	One-step microfluidics production of enzyme-loaded liposomes for the treatment of inflammatory diseases. Colloids and Surfaces B: Biointerfaces, 2021, 199, 111556.	5.0	23
9	Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury. Drug Delivery and Translational Research, 2021, 11, 397-410.	5.8	8
10	Liposomal Nanosystems in Rheumatoid Arthritis. Pharmaceutics, 2021, 13, 454.	4.5	19
11	Pyrazoles as novel protein tyrosine phosphatase 1B (PTP1B) inhibitors: An in vitro and in silico study. International Journal of Biological Macromolecules, 2021, 181, 1171-1182.	7.5	19
12	Optimization and Validation of an In Vitro Standardized Glycogen Phosphorylase Activity Assay. Molecules, 2021, 26, 4635.	3.8	7
13	Nano-based drug delivery systems used as vehicles to enhance polyphenols therapeutic effect for diabetes mellitus treatment. Pharmacological Research, 2021, 169, 105604.	7.1	17
14	Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution. International Journal of Pharmaceutics, 2021, 607, 121025.	5.2	5
15	Dry powder inhaler formulation of Cu,Zn-superoxide dismutase by spray drying: A proof-of-concept. Powder Technology, 2021, 389, 131-137.	4.2	8
16	Inhalable hydrophilic molecule-loaded liposomal dry powder formulations using supercritical CO2 – assisted spray-drying. Journal of CO2 Utilization, 2021, 53, 101709.	6.8	11
17	Insights on the Potential Preventive and Healing Effects of Flavonoids in Inflammatory Bowel Disease. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 38-66.	0.1	O
18	ASP-Enzymosomes with Saccharomyces cerevisiae Asparaginase II Expressed in Pichia pastoris: Formulation Design and In Vitro Studies of a Potential Antileukemic Drug. International Journal of Molecular Sciences, 2021, 22, 11120.	4.1	4

#	Article	IF	CITATIONS
19	Solid Dosage Forms of Biopharmaceuticals in Drug Delivery Systems Using Sustainable Strategies. Molecules, 2021, 26, 7653.	3.8	5
20	All-in-one microfluidic assembly of insulin-loaded pH-responsive nano-in-microparticles for oral insulin delivery. Biomaterials Science, 2020, 8, 3270-3277.	5.4	28
21	Targeting Cancer Resistance via Multifunctional Gold Nanoparticles. International Journal of Molecular Sciences, 2019, 20, 5510.	4.1	24
22	Animal models of acute gastric mucosal injury: Macroscopic and microscopic evaluation. Animal Models and Experimental Medicine, 2019, 2, 121-126.	3.3	40
23	Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury. Current Pharmaceutical Design, 2018, 24, 2692-2700.	1.9	5
24	Immortalization and characterization of a new canine mammary tumour cell line <scp>FR37 MT</scp> . Veterinary and Comparative Oncology, 2017, 15, 952-967.	1.8	9
25	Therapeutic activity of superoxide dismutase-containing enzymosomes on rat liver ischaemia-reperfusion injury followed by magnetic resonance microscopy. European Journal of Pharmaceutical Sciences, 2017, 109, 464-471.	4.0	16
26	From the Cover: Metabolism Modulation in Different Organs by Silver Nanoparticles: An NMR Metabolomics Study of a Mouse Model. Toxicological Sciences, 2017, 159, 422-435.	3.1	48
27	Development of New Contrast Agents for Imaging Function and Metabolism by Magnetic Resonance Imaging. Magnetic Resonance Insights, 2017, 10, 1178623X1772213.	2.5	5
28	Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents. Journal of Controlled Release, 2017, 245, 52-61.	9.9	64
29	Regulatory Development of Nanotechnology-Based Vaccines. , 2017, , 393-410.		5
30	Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach. , 2017, , 749-774.		7
31	Liposil Nanocarriers for Pharmaceutical Applications: Synthesis Innovations. Journal of Nanomedicine & Nanotechnology, 2017, 08, .	1.1	2
32	Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy. Pharmaceutical Research, 2016, 33, 1351-1358.	3.5	18
33	Microscopic Studies of Liver and Kidney in Mice Exposed to Silver Nanoparticles. Microscopy and Microanalysis, 2016, 22, 18-19.	0.4	0
34	Production of nano-solid dispersions using a novel solvent-controlled precipitation process â€" Benchmarking their in vivo performance with an amorphous micro-sized solid dispersion produced by spray drying. European Journal of Pharmaceutical Sciences, 2016, 93, 203-214.	4.0	16
35	Superoxide Dismutase Enzymosomes: Carrier Capacity Optimization, in Vivo Behaviour and Therapeutic Activity. Pharmaceutical Research, 2015, 32, 91-102.	3.5	31
36	Regulatory Aspects of Oncologicals: Nanosystems Main Challenges. Advances in Delivery Science and Technology, 2014, , 425-452.	0.4	14

#	Article	IF	Citations
37	Prophylactic Use of Liposomal Amphotericin B in Preventing Fungal Infections Early After Liver Transplantation: A Retrospective, Single-Center Study. Transplantation Proceedings, 2014, 46, 3554-3559.	0.6	4
38	New long circulating magnetoliposomes as contrast agents for detection of ischemia–reperfusion injuries by MRI. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 207-214.	3.3	22
39	Enhanced contrast efficiency in MRI by PEGylated magnetoliposomes loaded with PEGylated SPION: Effect of SPION coating and micro-environment. Materials Science and Engineering C, 2014, 43, 521-526.	7.3	33
40	Insights on the safety of carotenogenic Chlorella vulgaris in rodents. Algal Research, 2013, 2, 409-415.	4.6	14
41	Abstract 4521: A novel targeted triggered release nanoparticle against cancer cells of diverse histological origin, 2013, , .		0
42	Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine, 2012, 30, 6551-6558.	3.8	25
43	Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 281-290.	4.3	16
44	Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Research and Treatment, 2012, 133, 61-73.	2.5	54
45	Abstract C233: Limiting tumor invasion with multifunctional nanoparticle targeting the tumor microenvironment , 2011, , .		0
46	Targeting non-viral vectors to tumor cells and the tumor microenvironment. BMC Proceedings, 2010, 4, .	1.6	0
47	Abstract A129: Targeted delivery of therapeutics to tumor cells and the tumor microenvironment. , 2009, , .		1
48	Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids. Current Medicinal Chemistry, 2008, 15, 1586-1605.	2.4	168
49	Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. Journal of Controlled Release, 2007, 117, 186-195.	9.9	61
50	Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes. Journal of Controlled Release, 2005, 103, 419-434.	9.9	62
51	Liposomal Superoxide Dismutases and Their Use in the Treatment of Experimental Arthritis. Methods in Enzymology, 2005, 391, 395-413.	1.0	32
52	Biochemical changes in arthritic rats: dehydroascorbic and ascorbic acid levels. European Journal of Pharmaceutical Sciences, 2003, 18, 185-189.	4.0	10
53	Design and characterization of enzymosomes with surface-exposed superoxide dismutase. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 211-217.	2.6	30
54	Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 227-236.	2.6	102

#	Article	IF	CITATIONS
55	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharmaceutical Research, 2000, 17, 600-606.	3.5	44
56	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1419, 325-334.	2.6	101
57	Technetium-99m labelled liposomes to image experimental arthritis. Annals of the Rheumatic Diseases, 1997, 56, 369-373.	0.9	41
58	Liposomal formulations of Cu,Zn-superoxide dismutase: physico-chemical characterization and activity assessment in an inflammation model. Journal of Controlled Release, 1997, 43, 1-8.	9.9	30